Company Encyclopedia
View More
name
Invesco Dorsey Wright EM Markets Momentum ETF
PIE.US
News
View More

HBM Holdings Repurchases 100,000 Shares at HK$13.53 Each, Files Disclosure with HKEX

HBM Holdings Ltd. repurchased 100,000 shares at HK$13.53 each, totaling HKD 1,337,000, and filed a disclosure with the Hong Kong Stock Exchange. The shares are held as treasury shares.

Reuters·
HK
02142
+3.35%
Reuters·
HK
02142
+3.35%

Hbm climbs on progress of AstraZeneca collaboration

** Shares of Hbm Holdings climb 2.3% to HK$13.2, on course for the biggest one-day pct gain since Nov 14** Hbm said the scope of collaboration with AstraZeneca was further advanced following an amendment to an earlier agreement, aiming to develop next-generation biotherapeutics including antibody-drug conjugates and T cell engagers** The therapeutics developer for immuno-oncology and immunology diseases said the economic terms remain consistent with the financial framework established under the agreement ** YTD, stock up 590%, Hang Seng Biotech Index (.HSBIO) up 77.2%

Reuters·
US
AZN
-0.90%
HK
02142
+3.35%
Reuters·
US
AZN
-0.90%
HK
02142
+3.35%

HBM Holdings Enhances Collaboration with AstraZeneca for Biotherapeutic Development

HBM Holdings Ltd. has announced an enhancement in its collaboration with AstraZeneca to develop next-generation biotherapeutics. The amendment to their agreement expands the partnership's scope while maintaining original economic terms, highlighting their commitment to biotechnology expertise. HBM Holdings focuses on innovative therapeutics, including antibody-drug conjugates and T cell engagers, with a market cap of HK$11.39B. The latest analyst rating for HBM Holdings stock is a Hold with a HK$13.50 price target.

Tip Ranks·
US
AZN
-0.90%
HK
02142
+3.35%
UK
AZN
0.00%
Tip Ranks·
US
AZN
-0.90%
HK
02142
+3.35%
UK
AZN
0.00%
© 2025 Longbridge｜Disclaimer